The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review

Authors

Amanda Hunt
Victoria Qian
Hailey Olds
Steven Daveluy, Beaumont Health

Document Type

Article

Publication Date

7-2023

Publication Title

Dermatology and Therapy

Abstract

Hidradenitis suppurativa (HS) is a skin disease resulting from chronic, recurrent inflammation around hair follicles, characterized by proinflammatory cytokines such as IL-1, IL-17, IL-23, and TNF-α. While adalimumab, a TNF-α targeting human IgG monoclonal antibody, is the only approved treatment for HS, there are many other therapies being investigated now targeting other key players in inflammatory pathways such as the cytokines listed above, C5a in the complement pathway, and Janus kinase (JAK). This review discusses current clinical trials for biologics and small molecules, procedures, and wound dressings undergoing study in hidradenitis suppurativa.

Volume

13

Issue

7

First Page

1391

Last Page

1407

Recommended Citation

Hunt A, Qian V, Olds H, Daveluy S. The Current Clinical Trial Landscape for hidradenitis suppurativa: a narrative review. Dermatol Ther (Heidelb). 2023 Jul;13(7):1391-1407. doi: 10.1007/s13555-023-00935-x. PMID: 37261652.

DOI

10.1007/s13555-023-00935-x

ISSN

2193-8210

PubMed ID

37261652